PH 1 Study to Evaluate Safety and Tolerability of XmAb14045 in Patients With CD123-expressing Hematologic Malignancies

NCT02730312 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

120

Enrollment

INDUSTRY

Sponsor class

Conditions

Acute Myelogenous Leukemia
B-cell Acute Lymphoblastic Leukemia
Blastic Plasmacytoid Dendritic Cell Neoplasm
Chronic Myeloid Leukemia, Blast Crisis

Interventions

BIOLOGICAL: XmAb14045

Sponsor

Xencor, Inc.

Collaborators

[object Object]